ESMO25: On allosteric modulation in oncology, with Michael Lahn

Oncology

Interview at ESMO 2025 with Michael Lahn, iOnctura

At ESMO 2025, pharmaphorum had the pleasure of speaking with Michael Lahn, Chief Medical Officer at iOnctura, a clinical-stage precision oncology company combatting neglected and hard-to-treat cancers with a pipeline of first-in-class small molecules.

Lahn discusses allosteric modulation, autotaxin inhibition, and the Congress as a whole.

Watch this and other conversations from ESMO 2025 here.

Nicole Raleigh

20 November, 2025

ESMO 2025

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.